GlassScriptPhysician profile
Maged M Andrews
NPI 1477782894
$6,530.76
in general payments reported to CMS, 2019-2025
31 companies · $2,139 in 2025
The $2,139 reported for 2025 was more than what 97% of Anesthesiology providers received nationally (typical 2025 total: $58.09).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $230 · 2021: $663 · 2022: $887 · 2023: $1,099 · 2024: $1,513 · 2025: $2,139.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,698 · Education: $53.16.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,697.72 |
| Education | $53.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,419.67 | 2021-2025 | Tremfya, Stelara, Remicade |
| Takeda Pharmaceuticals U.S.A., INC. | $1,287.27 | 2020-2025 | Entyvio, Gattex |
| Abbvie INC. | $1,061.68 | 2020-2025 | Rinvoq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $939.67 | 2020-2025 | Xifaxan, Trulance |
| Qol Medical, LLC | $223.79 | 2021-2023 | Sucraid |
| Ipsen Biopharmaceuticals, INC | $170.51 | 2024-2025 | Iqirvo, Bylvay |
| Madrigal Pharmaceuticals | $162.11 | 2024-2025 | Rezdiffra, Resmetirom |
| Braintree Laboratories, INC. | $143.40 | 2021-2025 | Suflave, Sutab |
| Amgen INC. | $137.75 | 2021-2023 | Amjevita, Avsola |
| Phathom Pharmaceuticals, INC. | $137.34 | 2024-2025 | Voquezna |
| Intercept Pharmaceuticals, INC. | $132.49 | 2022-2025 | Ocaliva |
| Lilly USA, LLC | $126.88 | 2023-2025 | Omvoh |
| Regeneron Healthcare Solutions, INC. | $110.05 | 2022-2025 | Dupixent |
| Celltrion USA INC. | $102.20 | 2024-2025 | Zymfentra, Vegzelma |
| Aimmune Therapeutics, INC. | $61.76 | 2025 | Zenpep, Vowst |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $38.21 | 2025 | Wegovy |
| Fresenius Kabi USA, LLC | $34.86 | 2023 | Idacio |
| Digestive Care, INC. | $33.50 | 2025 | Pertzye |
| Enterra Medical, INC. | $27.09 | 2024 | |
| Ardelyx, INC. | $20.11 | 2025 | Ibsrela |
| Medtronic, INC. | $17.87 | 2025 | Interstim |
| Pharmacosmos Therapeutics INC. | $17.45 | 2020 | |
| Albireo Pharma, INC. | $15.74 | 2022 | |
| Alnylam Pharmaceuticals INC. | $15.38 | 2024 | Givlaari |
| Capsovision, INC. | $15.04 | 2024 | Capsocam Plus |
| Janssen Pharmaceuticals, INC | $14.68 | 2021 | |
| Ironwood Pharmaceuticals, INC | $13.88 | 2022 | |
| Biocon Biologics INC | $13.87 | 2023 | Hulio |
| Vivus LLC | $13.73 | 2021 | |
| W. L. Gore & Associates, INC. | $11.83 | 2022 | |
| Boston Scientific Corporation | $10.95 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maged Andrews listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.